The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

The condition MASH (Metabolic Dysfunction-Associated Steatohepatitis) is common and serious.

The stock market is abuzz as shares of Novo Nordisk (NVO) experience a notable rise following the recent approval of its weight loss medication, Wegovy, by the U.S. Food and Drug Administration (FDA) ...

Shares of Novo Nordisk (NVO) are making headlines as they rise sharply following the U.S. Food and Drug Administration's (FDA) recent approval of Wegovy for treating metabolic-associated ...

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

Chief Medical Officer of Northwestern Medicine’s Northwest region of hospitals Dr. Irfan Hafiz joins Bob Sirott to talk about when you should get your flu shot and how Omega-3 could help protect ...

The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

As appetite-suppressing drugs change the way people eat, businesses are adapting to GLP-1 users by offering smaller portions ...